Eversense 365 CGM Demonstrates Sustained Performance Over One-Year of Use

New real-world data shows strong patient adherence and positive glycemic outcomes with the world's first and only one-year continuous glucose monitoring system.

Mar. 14, 2026 at 3:06pm

Got story updates? Submit your updates here. ›

Senseonics, a medical technology company, has announced new data from a real-world evidence study that demonstrates the sustained performance and positive impact of its Eversense 365 continuous glucose monitoring (CGM) system across a full one-year period. The data, presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), show strong patient adherence, improved glucometrics, and positive hypoglycemic outcomes with the implantable, year-long CGM system.

Why it matters

The findings validate the promise of a year-long CGM system and its potential to transform diabetes management by providing patients with a full year of consistent, accurate glucose monitoring with minimal interruptions. The data suggest Eversense 365 can particularly benefit older adults and young adults, two populations that often struggle with glycemic control.

The details

The study evaluated the first 5,059 real-world Eversense 365 CGM sensors used by patients in the US. The analysis revealed an average transmitter wear time of 93.8%, with comparable results for the first and second six-month periods, indicating a year of consistent and meaningful system use. This resulted in a mean Glucose Management Indicator (GMI) of 7.14% and a mean Time in Range (TIR) of 66%, demonstrating effective glycemic control. Furthermore, over 75% of users achieved hypoglycemic targets, reinforcing the accuracy of Eversense 365 in low glucose ranges.

  • Eversense 365 was approved by the FDA in September 2024 and launched in the US in October 2024.
  • Eversense 365 received European CE Mark approval in January 2026, and Senseonics expects to launch the system in Germany, Italy, Spain, and Sweden in the coming months.

The players

Senseonics

A medical technology company focused on the development, manufacturing, and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes.

Francine Kaufman, M.D.

Chief Medical Officer at Senseonics.

Brian Hansen

Chief Commercial Officer at Senseonics.

Got photos? Submit your photos here. ›

What they’re saying

“The promise of a year-long CGM has now been demonstrated in the real world.”

— Francine Kaufman, M.D., Chief Medical Officer at Senseonics

“We are proud to present these data at ATTD, which is always a fantastic opportunity to connect with the diabetes ecosystem and discuss the latest developments in technology and care.”

— Brian Hansen, Chief Commercial Officer at Senseonics

What’s next

Senseonics plans to present a longer-term real-world analysis of the Eversense 365 system combined with the twiist Automated Insulin Delivery (AID) system later this year.

The takeaway

The real-world data on Eversense 365 demonstrate the potential of a long-term, implantable CGM system to transform diabetes management by providing patients with consistent, accurate glucose monitoring for an entire year with minimal interruptions, particularly benefiting older adults and young adults who often struggle with glycemic control.